Article
Oncology
May Tun Saung, Lorraine Pelosof, Sandra Casak, Martha Donoghue, Steven Lemery, Mengdie Yuan, Lisa Rodriguez, Peter Schotland, Meredith Chuk, Gina Davis, Kirsten B. Goldberg, Marc R. Theoret, Richard Pazdur, Lola Fashoyin-Aje
Summary: The FDA granted accelerated approval to nivolumab in combination with ipilimumab for the treatment of HCC based on data from cohort 4 of Check-Mate 040, showing comparable BICR-assessed ORR in all three arms at 31%-32%. Adverse events were consistent with known profiles of nivolumab and ipilimumab, with no new safety events identified.
Article
Medicine, Research & Experimental
Jialiang Luo, Lei Li, Zhengyumeng Zhu, Bo Chang, Fan Deng, Di Wang, Xiao Lu, Daming Zuo, Qingyun Chen, Jia Zhou
Summary: This study demonstrated that the combination of fucoidan and sorafenib could overcome sorafenib resistance in hepatocellular carcinoma cells by interacting with cell membrane EGFR and suppressing EGFR redistribution and downstream signaling. The simultaneous treatment of fucoidan and sorafenib might serve as a potential therapeutic strategy against sorafenib-resistant HCC.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Oncology
Qinqin Liu, Nan You, Jing Li, Ke Wu, Xuehui Peng, Zheng Wang, Liang Wang, Yinan Zhu, Lu Zheng
Summary: The study found that the combination of camrelizumab and sorafenib significantly improved the overall response rate and progression-free survival of patients with advanced HCC, but had no significant impact on overall survival. The combination therapy group exhibited more adverse events in terms of efficacy, but most of these adverse events were easily controlled after treatment. Further prospective randomized trials are needed to confirm the potential clinical benefits of this combination therapy.
FRONTIERS IN ONCOLOGY
(2021)
Article
Chemistry, Multidisciplinary
Mahmoud A. Younis, Ikramy A. Khalil, Yaser H. A. Elewa, Yasuhiro Kon, Hideyoshi Harashima
Summary: The usLNPs, composed of a novel pH-sensitive lipid, phospholipids, and a targeting peptide, demonstrated enhanced tumor accumulation, selectivity, and in vivo gene silencing. This combination therapy synergistically eradicated HCC in mice at a low dose of SOR and showed promising potential for clinical applications.
JOURNAL OF CONTROLLED RELEASE
(2021)
Article
Medicine, Research & Experimental
Shuhua Wei, Fenghua Wei, Mengyuan Li, Yuhan Yang, Jingwen Zhang, Chunxiao Li, Junjie Wang
Summary: Sorafenib, a multi-kinase inhibitor, has been approved for cancer treatment, especially hepatocellular carcinoma (HCC). However, many cancer patients acquire drug resistance to sorafenib in subsequent treatment, and the immunological mechanisms behind this resistance are still unclear. This review focuses on the immunoregulatory effects of sorafenib on the tumor microenvironment, the potential immunological mechanisms of therapeutic resistance, and the combination of sorafenib with immunotherapy to improve efficacy.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Oncology
Giuseppa Augello, Maria Rita Emma, Antonina Azzolina, Roberto Puleio, Lucia Condorelli, Antonella Cusimano, Lydia Giannitrapani, James A. McCubrey, Juan Lucio Iovanna, Melchiorre Cervello
Summary: The study revealed that NUPR1 knock-down impaired autophagic flux, increasing cell sensitivity to sorafenib, and activated the p73 signaling pathway, enhancing the anti-tumor effects of the drug. Combined therapy with the p73 activator NSC59984 and sorafenib showed synergistic suppression of tumor growth, suggesting a novel approach for HCC treatment.
Article
Pharmacology & Pharmacy
Qiu-Chen Bi, Zhi-Qiang Deng, Yang-Feng Lv, Yue Liu, Chuan-Sheng Xie, Yuan-qiao He, Qun Tang
Summary: This study found that low Pi stress can enhance the sensitivity of hepatocellular carcinoma to sorafenib by suppressing the migration and invasion of cancer cells and inhibiting angiogenesis. Low Pi stress also decreased the viability of sorafenib-resistant cells by directly regulating the expression of specific proteins. In vivo analysis confirmed the enhanced sensitivity of hepatocellular carcinoma to sorafenib under low Pi stress. Overall, low Pi stress can improve the efficacy of sorafenib in treating hepatocellular carcinoma and expand the indications for sevelamer.
BIOCHEMICAL PHARMACOLOGY
(2023)
Review
Medicine, Research & Experimental
Fan-Hua Kong, Qi-Fa Ye, Xiong-Ying Miao, Xi Liu, Si-Qi Huang, Li Xiong, Yu Wen, Zi-Jian Zhang
Summary: Hepatocellular carcinoma (HCC) is the most common type of liver cancer and has high resistance to traditional chemotherapy. Sorafenib, an oral kinase inhibitor, has shown improved survival rates for advanced liver cancer patients, but its clinical application is limited by poor solubility and low bioavailability. Nanoparticles have been explored to enhance the therapeutic efficacy of sorafenib in treating HCC, offering new hope for liver cancer treatment.
Article
Cell Biology
You-Liang Lai, Kai-Hung Wang, Hsing-Pang Hsieh, Wan-Ching Yen
Summary: DBPR114 showed activity against HCC tumor cell proliferation in vitro regardless of p53 alteration status and tumor grade. It induced growth inhibition in HCC cells through apoptosis induction, cell cycle arrest, and polyploidy formation. DBPR114 also exhibited anti-angiogenic effects and significantly inhibited tumor growth in multiple HCC tumor xenograft models.
JOURNAL OF BIOMEDICAL SCIENCE
(2022)
Article
Chemistry, Multidisciplinary
Yao Chen, Dong Zhao, Feng Xiao, Xuanyu Li, Jia'an Li, Zhenwei Su, Xingyu Jiang
Summary: In this study, a microfluidic chip was used to sequentially assemble multi-component nanoparticles, including therapeutic drugs and siRNA, with high encapsulation efficiencies and efficient tumor treatment effects.
ADVANCED MATERIALS
(2023)
Article
Biochemistry & Molecular Biology
Tingting Shi, Hisakazu Iwama, Koji Fujita, Hideki Kobara, Noriko Nishiyama, Shintaro Fujihara, Yasuhiro Goda, Hirohito Yoneyama, Asahiro Morishita, Joji Tani, Mari Yamada, Mai Nakahara, Kei Takuma, Tsutomu Masaki
Summary: The study evaluated the inhibitory effect of lenvatinib on sorafenib-resistant HCC cells, finding that lenvatinib suppresses cell proliferation mainly by inducing G1 cell cycle arrest through ERK signaling. The results suggest that lenvatinib may be a suitable second-line therapy for patients with sorafenib-resistant HCC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Biochemistry & Molecular Biology
Pei-Wei Shueng, Hui-Wen Chan, Wei-Chan Lin, Deng-Yu Kuo, Hui-Yen Chuang
Summary: Sorafenib is an effective drug for hepatocellular carcinoma, but resistance often occurs. This study found that resistance to sorafenib could be reversed by inhibiting fatty acid synthesis using orlistat, and this combination treatment enhanced cell killing in hepatocellular carcinoma by altering cell metabolism.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Medicine, Research & Experimental
Guifang Gan, Zhaopeng Shi, Chengfang Shangguan, Jieying Zhang, Yuan Yuan, Lei Chen, Weiren Liu, Biao Li, Songshu Meng, Wujun Xiong, Jun Mi
Summary: The study demonstrates that 3-HAA sensitizes HCC cells to sorafenib by upregulating phosphatases, indicating it as a promising molecule for HCC therapy.
Article
Chemistry, Multidisciplinary
Ji Feng, Pei-zhi Lu, Guang-zhi Zhu, Shing Chung Hooi, Yong Wu, Xiao-wei Huang, Hui-qi Dai, Pan-hong Chen, Zhong-jie Li, Wen-jing Su, Chuang-ye Han, Xin-ping Ye, Tao Peng, Jing Zhou, Guo-dong Lu
Summary: ACSL4 plays a crucial role in sorafenib treatment and its high expression may predict sensitivity of HCC patients to sorafenib. The findings of this study could have important translational impacts in the precise treatment of HCC patients.
ACTA PHARMACOLOGICA SINICA
(2021)
Review
Oncology
Yongsheng Pang, Aydin Eresen, Zigeng Zhang, Qiaoming Hou, Yining Wang, Vahid Yaghmai, Zhuoli Zhang
Summary: Sorafenib is an approved oral medication for treating unresectable hepatocellular carcinoma. It targets growth factor receptors to reduce angiogenesis and inhibits cell proliferation. However, its effectiveness is limited and it can cause significant toxicities.
AMERICAN JOURNAL OF CANCER RESEARCH
(2022)